Treatment of Helicobacter pylori Infection 2013.

Hdl Handle:
http://hdl.handle.net/10147/302015
Title:
Treatment of Helicobacter pylori Infection 2013.
Authors:
O'Connor, Anthony; Molina-Infante, Javier; Gisbert, Javier P; O'Morain, Colm
Affiliation:
Department of Gastroenterology, Adelaide and Meath Hospital incorporating the National Children's Hospital/Trinity College Dublin, Tallaght, Dublin, Ireland.
Citation:
Treatment of Helicobacter pylori Infection 2013. 2013, 18 Suppl 1:58-65 Helicobacter
Journal:
Helicobacter
Issue Date:
Sep-2013
URI:
http://hdl.handle.net/10147/302015
DOI:
10.1111/hel.12075
PubMed ID:
24011247
Abstract:
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2012 up to March 2013. To begin with, the updated European Consensus Guidelines were published last year, highlighting the role of bismuth and nonbismuth quadruple regimen as first-line treatments. Cure rates for standard triple therapy remain acceptable in quite a few settings nowadays, and some reports on innovative triple therapies look promising. One study evaluating bismuth quadruple therapy as first-line therapy was reported. Regarding nonbismuth quadruple regimens, there is a trend of superiority emerging for the "concomitant" therapy over the "sequential" regimen. "Hybrid" therapy, a combination of sequential and concomitant therapy, has also shown advantage over sequential therapy. Levofloxacin-based therapies appear to be useful and versatile in second- and third-line therapies, with interesting results for newer generation quinolones, which may partially overcome antibiotic resistance. Some promising works have been reported for bismuth-based rescue therapy, using individualized therapies upon antimicrobial information, as well as for rifabutin fourth-line therapy. Probiotics appear to have an effect in terms of reducing side effects and improving compliance, but data on improvement of eradication rates remain controversial.
Item Type:
Article
Language:
en
ISSN:
1523-5378

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connor, Anthonyen_GB
dc.contributor.authorMolina-Infante, Javieren_GB
dc.contributor.authorGisbert, Javier Pen_GB
dc.contributor.authorO'Morain, Colmen_GB
dc.date.accessioned2013-09-20T15:13:19Z-
dc.date.available2013-09-20T15:13:19Z-
dc.date.issued2013-09-
dc.identifier.citationTreatment of Helicobacter pylori Infection 2013. 2013, 18 Suppl 1:58-65 Helicobacteren_GB
dc.identifier.issn1523-5378-
dc.identifier.pmid24011247-
dc.identifier.doi10.1111/hel.12075-
dc.identifier.urihttp://hdl.handle.net/10147/302015-
dc.description.abstractThis review summarizes important studies regarding Helicobacter pylori therapy published from April 2012 up to March 2013. To begin with, the updated European Consensus Guidelines were published last year, highlighting the role of bismuth and nonbismuth quadruple regimen as first-line treatments. Cure rates for standard triple therapy remain acceptable in quite a few settings nowadays, and some reports on innovative triple therapies look promising. One study evaluating bismuth quadruple therapy as first-line therapy was reported. Regarding nonbismuth quadruple regimens, there is a trend of superiority emerging for the "concomitant" therapy over the "sequential" regimen. "Hybrid" therapy, a combination of sequential and concomitant therapy, has also shown advantage over sequential therapy. Levofloxacin-based therapies appear to be useful and versatile in second- and third-line therapies, with interesting results for newer generation quinolones, which may partially overcome antibiotic resistance. Some promising works have been reported for bismuth-based rescue therapy, using individualized therapies upon antimicrobial information, as well as for rifabutin fourth-line therapy. Probiotics appear to have an effect in terms of reducing side effects and improving compliance, but data on improvement of eradication rates remain controversial.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Helicobacteren_GB
dc.titleTreatment of Helicobacter pylori Infection 2013.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Gastroenterology, Adelaide and Meath Hospital incorporating the National Children's Hospital/Trinity College Dublin, Tallaght, Dublin, Ireland.en_GB
dc.identifier.journalHelicobacteren_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.